Author

David C. Cunningham

Observed name: David Cunningham

Institutions: Royal Marsden NHS Foundation Trust, Royal Marsden Hospital

Observed institutions: Royal Marsden NHS Foundation Trust, Royal Marsden Hospital

OpenAlex ID: A5159942192

A pivotal Phase 2 study of derazantinib for previously-treated, locally advanced or metastatic cholangiocarcinoma with FGFR2 aberrations: FIDES-01

2026 · Mitesh J. Borad, Michele Droz dit Busset, et al. · Hepatology

Case Series: Severe cholangitis as an immune checkpoint inhibitor induced adverse event in four cases: management and treatment options including tocilizumab and ursodeoxycholic acid

2026 · Darina Kohoutova, Joshua Shur, et al. · Frontiers in Immunology

Works count: 2

Citation count:

H-index:

I10-index: